International Journal of Hematology

, Volume 98, Issue 4, pp 463–471 | Cite as

Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group

  • Yoshikiyo Ito
  • Toshihiro MiyamotoEmail author
  • Tomohiko Kamimura
  • Ken Takase
  • Hideho Henzan
  • Yasuo Sugio
  • Koji Kato
  • Yuju Ohno
  • Tetsuya Eto
  • Takanori Teshima
  • Koichi Akashi
Original Article


Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning (P = 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood (P = 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % (P = 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD (P = 0.01), but not better PFS compared with patients who had no acute GVHD (P = 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL.


Allogeneic stem cell transplantation Follicular lymphoma 



We thank the nursing staff who cared for the patients at the Fukuoka BMT group. This work was supported, in part, by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology in Japan (23390254 & 24659462 to T.M.).


  1. 1.
    Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470–80.PubMedGoogle Scholar
  2. 2.
    Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–7.PubMedGoogle Scholar
  3. 3.
    Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100:3108–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011;17:1051–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Reddy N, Greer JP, Goodman S, Engelhardt B, Oluwole O, Jagasia MH, et al. Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma. Bone Marrow Transplant. 2012;47:1318–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Ono Y, Mori T, Kato J, Yamane A, Shimizu T, Kikuchi T, et al. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. Am J Hematol. 2012;87:929–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005;36:205–13.PubMedGoogle Scholar
  10. 10.
    Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, et al. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. Am J Hematol. 2012;87:770–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Cheson BD. Targeted treatment and new agents in follicular lymphoma. Int J Hematol. 2010;92:5–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Grillo-Lopez AJ. Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol. 2002;76:385–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Swerdllow S, Campo E, Harris NL (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. France IARC (in press).Google Scholar
  14. 14.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation. 2011;92:366–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Minagawa K, Yamamori M, Katayama Y, Matsui T. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis. Int J Hematol. 2012;96:10–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.PubMedCrossRefGoogle Scholar
  18. 18.
    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med. 1993;328:593–602.PubMedCrossRefGoogle Scholar
  20. 20.
    Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.PubMedCrossRefGoogle Scholar
  21. 21.
    Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–9.PubMedGoogle Scholar
  22. 22.
    Cohen Y, Solal-Celigny P, Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haematologica. 2003;88:811–23.PubMedGoogle Scholar
  23. 23.
    Salles G, Ghesquieres H. Current and future management of follicular lymphoma. Int J Hematol. 2012;96:544–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012;119:6373–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;14:236–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ, et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2009;147:719–28.PubMedCrossRefGoogle Scholar
  27. 27.
    Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant. 2011;17:1395–403.PubMedCrossRefGoogle Scholar
  28. 28.
    Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28:3695–700.PubMedCrossRefGoogle Scholar
  29. 29.
    Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Diez-Martin JL, et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica. 2010;95:1176–82.PubMedCrossRefGoogle Scholar
  30. 30.
    Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:211–7.PubMedCrossRefGoogle Scholar
  31. 31.
    van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832–6.PubMedGoogle Scholar
  32. 32.
    Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–78.PubMedCrossRefGoogle Scholar
  33. 33.
    van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14:418–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–8.PubMedGoogle Scholar
  36. 36.
    Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.PubMedGoogle Scholar
  37. 37.
    Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R, et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia. 2011;25:551–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007;92:627–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Khouri IF, Saliba R, Korbling M, Alousi AM, Popat UR, Anderlini P, et al. Bendamustine in combination with fludarabine and rituximab: a novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. ASCO Meet Abstr. 2011;29:e18511.Google Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Yoshikiyo Ito
    • 1
  • Toshihiro Miyamoto
    • 2
    • 7
    Email author
  • Tomohiko Kamimura
    • 1
  • Ken Takase
    • 3
    • 5
  • Hideho Henzan
    • 3
  • Yasuo Sugio
    • 4
  • Koji Kato
    • 2
  • Yuju Ohno
    • 4
  • Tetsuya Eto
    • 3
  • Takanori Teshima
    • 6
  • Koichi Akashi
    • 2
  1. 1.Department of HematologyHarasanshin HospitalFukuokaJapan
  2. 2.Department of Medicine and Biosystemic ScienceGraduate School of Medical Science, Kyushu UniversityFukuokaJapan
  3. 3.Department of HematologyHamanomachi HospitalFukuokaJapan
  4. 4.Department of Internal MedicineKitakyushu Municipal Medical CenterKitakyushuJapan
  5. 5.Department of HematologyNational Kyushu Medical CenterFukuokaJapan
  6. 6.Department of Hematology and OncologyHokkaido University Graduate School of MedicineSapporoJapan
  7. 7.Medicine and Biosystemic ScienceKyushu University Graduate School of Medical SciencesFukuokaJapan

Personalised recommendations